Clinical Practice Insights: Pharmacists Managing Advanced Endometrial Cancer

This episode, titled ‘Clinical Practice Insights: Pharmacists Managing Advanced Endometrial Cancer,’ featured panelists discussing the following critical questions:

How do recommendations for biomarker testing specifically apply to endometrial cancer?

What patient characteristics influence the selection of immunotherapy within endometrial cancer?

Led by the moderator, Megan May, the expert Oncology Pharmacists discussed the necessity of universal molecular profiling for all patients with endometrial cancer, emphasizing the four molecular subgroups defined by the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria: POLE-mutated, mismatch repair deficient (dMMR), p53-abnormal, and no specific molecular profile (NSMP). The panelists, including Jennifer MacDonald, Erin Zacholski, and Justina Salib, examined how these biomarkers, alongside histology and HER2 status, are predictive of response and essential for precision medicine. Furthermore, the experts explored how clinical factors such as comorbidities, autoimmune disease history, and the presence of measurable disease influence the choice between agents like dostarlimab and pembrolizumab.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Therapeutic Sequencing and NCCN Guidelines in Endometrial Cancer,’ features the panelists advancing their conversation on endometrial cancer and focusing on the integration of HER2-targeted therapies and a review of the latest NCCN Guideline recommendations for dMMR and pMMR populations.